技术与痴呆症 会议前会议
Franco Javier Ferrante1,2,3, Gonzalo Nicolás Pérez1,2,3, Joaquín Ponferrada2
1Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 23, 2025
概括
检查真实语言工具包 (TELL) 2.0 提高了使用语音生物标志物的痴呆症评估. 新功能改善了数据收集和分析,在区分疾病与健康对照时达到85-93%的准确性.
科学领域:
- 神经语言学和计算语言学
- 生物医学工程和健康信息学
背景情况:
- 检查真实语言工具包 (TELL) 是一个开发用于收集语音样本和提取语音生物标志物的网络应用程序,用于检测痴呆症.
- 最初的TELL版本成功支持临床评估,包括在资源不足的地区.
- TELL 2.0 已经开发了先进的功能,用于改善痴呆症研究中的数据处理和分析.
研究的目的:
- 推出TELL 2.0,这是Toolkit的升级版本,用于检查仿真语言,并增强了痴呆症评估的功能.
- 扩大语音生物标志物提取能力,以实现更广泛,更有效的痴呆症评估.
- 整合新的,可解释的语音指标和先进的可视化工具,用于临床应用.
主要方法:
- TELL 2.0 包含了显著的后端和前端改进,支持基于视频通话和离线数据采集的无损音频和本地转录.
- 一个全面的音频标准化管道 (幅度规范,降噪,频道协调) 已经实施.
- 整合了词汇检索,运动语言,语义记忆和自我引用语言的新可解释的指标,以及对痴呆症概况的机器学习预测.
主要成果:
- 在不同的数据收集模式中,表现出一致的音频和转录质量.
- 新的语音指标准确地将痴呆症患者与健康对照者区分开来,达到85-93%的准确性.
- 更新的可视化界面为临床医生提供可操作的见解,将指标与神经心理学框架对齐.
结论:
- TELL 2.0显著提高了用于痴呆症评估的语音生物标志物的可访问性和影响,基于其前身的成功.
- 研究驱动的开发将先进的发现转化为用于痴呆症评估的实用,可扩展和具有成本效益的工具.
- TELL 2.0代表了利用语音分析进行早期和准确的痴呆症检测的重大进展.
相关概念视频
01:30Dementia
482
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
482
01:22Alzheimer's Disease: Treatment
744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:15Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K